Get started
Author

Michèle Voegeli

Observed names: M Voegeli, M. Voegeli, Michele Voegeli, Michèle Voegeli, Voegeli, Michele
OpenAlex ID: A5022825869
Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study
2016 · Viktor H. Koelzer, Sacha I. Rothschild, et al. · Journal for ImmunoTherapy of Cancer · 201
PDF
Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland
2020 · A. A. Moccia, S. Aeppli, et al. · Hematological Oncology · 15
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)
2023 · Urban Novak, Martin Fehr, et al. · EClinicalMedicine · 13
PDF
Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year update
2025 · Eva Kimby, Sämi Schär, et al. · Blood Advances · 8
Infusion Speed-Escalation Trial To Give Full-Dose Rituximab in One Hour without Steroids Pre-Medication.
2005 · Michele Ghielmini, Laura Negretti, et al. · Blood · 8
Sakk 36/13 ‐ Ibrutinib Plus Bortezomib and Ibrutinib Maintenance for Relapsed and Refractory Mantle Cell Lymphoma: Final Report of a Phase I/ii Trial of the European Mcl Network
2021 · U. Novak, M. Fehr, et al. · Hematological Oncology · 5
PDF
Y90‐Ibritumomab tiuxetan (Y90‐IT) and high‐dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05)
2016 · Michèle Voegeli, Stephanie Rondeau, et al. · Hematological Oncology · 5
273 | Real‐world Outcomes of Pirtobrutinib in Relapsed/refractory Mantle Cell Lymphoma: a Multicenter Analysis With a Control Cohort From the European Mcl Registry
2025 · E. Aydilek, F. Schwarz, et al. · Hematological Oncology · 1
PDF
Long-Term Efficacy of a 6-Month Regimen of Rituximab and Lenalidomide in Follicular Lymphoma Patients in Need of First Therapy: Updated Analysis of the SAKK 35/10 Randomized Trial
2023 · Emanuele Zucca, Saemi Schaer, et al. · Blood · 1
PDF
Prognostic Factors in Elderly Patients With Classical Hodgkin Lymphoma ‐ a Joint Analysis of Two Clinical Databases
2021 · M Fehr, N Lang, et al. · Hematological Oncology · 1
Neoadjuvante, adjuvante und palliative onkologische Therapie beim kolorektalen Karzinom
2018 · Michèle Voegeli, Andreas Wicki · Therapeutische Umschau · 1
Obstruktive Pyelonephritis
2016 · Stephan Kiss, Fabio Nussberger, et al. · Forum Médical Suisse ‒ Swiss Medical Forum · 1
A modern approach to rectal cancer
2026 · Jasmin Zeindler, Marionna Cathomas, et al. · European surgery. Supplement/European surgery
PDF
Precision Oncology in Older Cancer Patients: A Single-Center Experience
2024 · Meret Petitat-Berli, Marie Knufinke, et al. · International Journal of Molecular Sciences
PDF
SIOG2024-1-P-022 Routine serum biomarkers as risk stratification parameters for older pancreatic cancer patients. Reports from a single center swiss cohort study
2024 · E.D. Chiru, R. Rosenberg, et al. · Journal of Geriatric Oncology
Abstract 3680: Prognostic value of serum biomarkers in pancreatic adenocarcinoma: Results from a Swiss single center cohort analysis
2024 · Elena D. Chiru, Marie Knufike, et al. · Cancer Research
Clinical Characteristics and Outcome of Patients With Hodgkin's Lymphoma Older Than 60 Years Treated in Switzerland Over the Last 17 Years
2019 · S. Aeppli, A. Moccia, et al. · Hematological Oncology
PDF
Y90-ibritumomab tiuxetan (Y90-IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation (ASCT) for elderly patients with lymphoma in relapse or resistant to chemotherapy: A feasibility trial (SAKK 37/05).
2013 · Michele Voegeli, Stephanie Rondeau, et al. · Journal of Clinical Oncology
Works count: 19
Citation count: 260
H-index: 5
I10-index: 3
Year
Topic
Type